相关实验视频
Updated: Mar 15, 2026

09:42
A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
Published on: June 4, 2021
3.6K
儿童的后病毒抗PF4免疫血栓形成:叙述性综述与实用指导
Günalp Uzun1, Martin Olivieri2, Tamam Bakchoul1
1Institute for Clinical and Experimental Transfusion Medicine, University Hospital of Tübingen, Tübingen, Germany.
Hamostaseologie
|March 13, 2026
概括
后病毒抗血小板因子4 (PF4) 免疫血栓是儿童罕见但严重的疾病,在病毒感染后引起血栓. 由于其潜在的致命性质,早期诊断和治疗至关重要.
科学领域:
- 儿科血液学 儿科血液学
- 免疫学 免疫学 免疫学
- 传染性疾病 传染性疾病
背景情况:
- 后病毒抗血小板因子4 (PF4) 免疫血栓瘤是一种新兴的儿科疾病.
- 它呈现出血小板减少,血栓形成和D-二次体水平升高,通常是在腺病毒感染后出现的.
研究的目的:
- 审查儿科病例和后病毒性抗PF4免疫血栓的机制研究.
- 专注于病理生理学,差异诊断,实验室评估和治疗策略.
主要方法:
- 通过PubMed和参考查对儿科病例和机理学研究进行系统审查.
- 对临床表现,实验室发现和治疗结果的分析.
主要成果:
- 确定了10名儿科患者,死亡率为20%.
- 常见的表现包括严重的头痛和神经缺陷5-14天后病毒性疾病.
- 针对PF4的特定测定结果呈阳性,使其与肝素诱导的血小板缩症区别开来.
结论:
- 后病毒抗PF4免疫血栓是罕见的,可能致命的,未被认可的儿科疾病.
- 基于有限的证据提出的诊断和治疗方法.
- 对于标准化标准和基于证据的协议,需要进一步的研究.
相关概念视频
Venous Thrombosis III: Interprofessional Care
449
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
449
Venous Thrombosis I: Introduction
622
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
622
Venous Thrombosis IV: Nursing Management
354
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
354
Disorders of Hemostasis
2.6K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.6K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.2K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
631
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
631

